Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119599 | 0.88 | PDE2A (0.41) | NUDT1TGFBR1TGFBR2JAK2JAK1 | |
| SCHEMBL20119765 | 0.85 | TGFBR1 (0.40) | TGFBR1TGFBR2PTK2CLK2AURKB | |
| SCHEMBL20119751 | 0.84 | MEN1 (0.44) | PTK2CYP1A2CYP3A4CLK2AURKB | |
| SCHEMBL20119598 | 0.80 | KCNH3 (0.43) | KCNH3JAK2JAK1TYK2JAK3 | |
| SCHEMBL20119397 | 0.79 | PDE5A (0.48) | KCNH3JAK2PDE2A | |
| SCHEMBL29833956 | 0.79 | PDE5A (0.48) | KCNH3JAK2PDE2A | |
| SCHEMBL20119612 | 0.78 | EGFR (0.38) | NUDT1TGFBR1TGFBR2JAK2JAK1 | |
| SCHEMBL20119919 | 0.78 | PKM (0.50) | CYP1A2CYP3A4CLK4 | |
| SCHEMBL20119509 | 0.76 | DYRK3 (0.40) | NUDT1TGFBR1TGFBR2JAK2JAK1 | |
| SCHEMBL20119891 | 0.76 | APP (0.48) | JAK2JAK1TYK2JAK3LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KCNH3 3654/4885NUDT1 998/4885TGFBR1 4875/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KCNH3 3654/4885NUDT1 998/4885TGFBR1 4875/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KCNH3 3654/4885NUDT1 998/4885TGFBR1 4875/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KCNH3 3654/4885NUDT1 998/4885TGFBR1 4875/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KCNH3 3654/4885NUDT1 998/4885TGFBR1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.